Imugene Ltd Notches Third Response in Azer Cel BTKi Cohort [VIDEO]
Imugene's azer-cel BTKi trial has now recorded three responses across five patients in its concurrent BTKi cohort — including both Follicular Lymphoma patients treated to date — strengthening the early efficacy signal in a heavily pre-treated population within a US$12 billion market.
Key Takeaways
- Imugene reported a third patient response in the concurrent BTKi cohort of its azer-cel Phase 1b trial on 27 July 2026, with the second Follicular Lymphoma patient achieving a partial response at Day 28 after previously progressing on BTKi therapy.
- Both Follicular Lymphoma patients treated in the concurrent BTKi cohort have now responded, giving the cohort three responses across five patients dosed to date.
- All patients enrolled in the concurrent BTKi cohort have relapsed on or are refractory to BTKi therapy, targeting a high-unmet-need population within a global BTKi market valued at approximately US$12.0 billion in 2025.
- Azer-cel is an off-the-shelf, allogeneic CAR T cell therapy that can be administered within days, avoiding the three-to-six week manufacturing lead time required for autologous CAR T products.
- Azer-cel holds dual FDA Fast Track Designation across CLL/SLL and Marginal Zone Lymphoma, secured in June 2026, with enrolment continuing across ten US and five Australian trial sites.
![4DMEDICAL Ltd Eyes US$20M Veterans Lung Imaging Pilot in Bipartisan Bill [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F50ee8fd8-6e27-47e9-8f8b-bc44aecfe8a02Fimage_0.jpg)
![Immuron Ltd Posts AUD$7.7M FY26 Sales After Four Quarters of Growth [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F277adf25-75c7-41c7-9122-1c9b621267252Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Appoints Nasdaq Pharma Chair Troy Valentine [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fc2e5bc46-118e-4f4a-af83-4a9b296665f22Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.